Crossmark

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

Crossref DOI link: https://doi.org/10.1007/s40744-023-00544-2

Published Online: 2023-03-25

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ye, Hua

Liu, Shengyun

Xu, Jian

Chai, Kexia

He, Dongyi

Fang, Yongfei

Xie, Qibing

Liu, Huaxiang

Liu, Ying

Hua, Bingzhu

Hu, Jiankang

Zhang, Zhiyi

Zhou, Mingxuan

Zhao, Dongbao

Li, Yan

Jiang, Zhenyu

Wang, Meimei

Li, Jingyang

Zhang, Zhuoli

Li, Xiaomei

Li, Yang

Sun, Erwei

Bi, Liqi

Wei, Wei

Tie, Ning

He, Lan

Huang, Xiangyang

Zhang, Yan

Huang, Qingchun

Wang, Xiaofei

Liu, Xiangyuan

Li, Jing

Su, Yin https://orcid.org/0000-0003-1364-1598
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03478111 at ClinicalTrials.gov

Documents that mention this clinical trial

Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade® in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis
https://doi.org/10.1007/s12325-022-02396-8

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
https://doi.org/10.1007/s40744-023-00544-2
Funding

Funding for this research was provided by:

Chinese National Key Technology R&D Program (2018ZX09301002-001)
License Information

Text and Data Mining valid from 2023-03-25

Version of Record valid from 2023-03-25
More Information

Article History

Received: 11 January 2023

Accepted: 20 February 2023

First Online: 25 March 2023

Document is current

Any future updates will be listed below